Data as of Jul 31
| +0.01 / +1.96%|
The 2 analysts offering 12-month price forecasts for Boston Therapeutics Inc have a median target of 1.46, with a high estimate of 1.80 and a low estimate of 1.12. The median estimate represents a +180.77% increase from the last price of 0.52.
The current consensus among 1 polled investment analysts is to Buy stock in Boston Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.